A citation-based method for searching scientific literature

César Serrano. Curr Opin Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Jason Gotlib, Aaron T Gerds, Prithviraj Bose, Mariana C Castells, Michael W Deininger, Ivana Gojo, Krishna Gundabolu, Gabriela Hobbs, Catriona Jamieson, Brandon McMahon,[...]. J Natl Compr Canc Netw 2018
17
100

How "benign" is cutaneous mastocytosis? A Danish registry-based matched cohort study.
Line Kibsgaard, Mette Deleuran, Carsten Flohr, Sinéad Langan, Anne Braae Olesen, Christian Vestergaard. Int J Womens Dermatol 2020
2
100


Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Arturo Vega-Ruiz, Jorge E Cortes, Matjaz Sever, Taghi Manshouri, Alfonso Quintás-Cardama, Raja Luthra, Hagop M Kantarjian, Srdan Verstovsek. Leuk Res 2009
96
100

Novel approaches to treating advanced systemic mastocytosis.
J A Gilreath, L Tchertanov, M W Deininger. Clin Pharmacol 2019
14
100

Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.
Peter Valent, Cem Akin, Karin Hartmann, Gunnar Nilsson, Andreas Reiter, Olivier Hermine, Karl Sotlar, Wolfgang R Sperr, Luis Escribano, Tracy I George,[...]. Cancer Res 2017
125
100

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.
Kerstin Maria Kampa-Schittenhelm, Julia Frey, Lara A Haeusser, Barbara Illing, Ashly A Pavlovsky, Gunnar Blumenstock, Marcus Matthias Schittenhelm. Oncotarget 2017
10
100

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Sophie Georgin-Lavialle, Ludovic Lhermitte, Felipe Suarez, Ying Yang, Sébastien Letard, Katia Hanssens, Frédéric Feger, Amédée Renand, Chantal Brouze, Danielle Canioni,[...]. Eur J Haematol 2012
37
100

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Ellen Weisberg, Chengcheng Meng, Abigail E Case, Martin Sattler, Hong L Tiv, Prafulla C Gokhale, Sara J Buhrlage, Xiaoxi Liu, Jing Yang, Jinhua Wang,[...]. Br J Haematol 2019
14
100

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Karoline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, Gregor Hörmann, Uwe Rix, Keiryn L Bennett, Emir Hadzijusufovic, Renata A Meyer, Winfried F Pickl, Jason Gotlib,[...]. Blood 2011
61
100

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Karoline V Gleixner, Matthias Mayerhofer, Karl J Aichberger, Sophia Derdak, Karoline Sonneck, Alexandra Böhm, Alexander Gruze, Puchit Samorapoompichit, Paul W Manley, Doriano Fabbro,[...]. Blood 2006
192
100


Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Johannes Lübke, Nicole Naumann, Sebastian Kluger, Juliana Schwaab, Georgia Metzgeroth, Erica Evans, Alexandra K Gardino, Christoph Lengauer, Wolf-Karsten Hofmann, Alice Fabarius,[...]. Leukemia 2019
20
100


IFNalpha treatment in systemic mastocytosis.
T Lehmann, B Lämmle. Ann Hematol 1999
20
100



Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
D J DeAngelo, T I George, A Linder, C Langford, C Perkins, J Ma, P Westervelt, J D Merker, C Berube, S Coutre,[...]. Leukemia 2018
52
100

Response to interferon alfa-2b in a patient with systemic mastocytosis.
H C Kluin-Nelemans, J H Jansen, H Breukelman, B G Wolthers, P M Kluin, H M Kroon, R Willemze. N Engl J Med 1992
182
100

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
64
100

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
Animesh Pardanani, Ken-Hong Lim, Terra L Lasho, Christy Finke, Rebecca F McClure, Chin-Yang Li, Ayalew Tefferi. Blood 2009
118
100

Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis.
Ayalew Tefferi, Sahrish Shah, Kaaren K Reichard, Curtis A Hanson, Animesh Pardanani. Am J Hematol 2019
8
100

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
100


Gastrointestinal stromal tumor: a review of current and emerging therapies.
Bayan Al-Share, Abdulrahman Alloghbi, Mohammed Najeeb Al Hallak, Hafiz Uddin, Asfar Azmi, Ramzi M Mohammad, Steve H Kim, Anthony F Shields, Philip A Philip. Cancer Metastasis Rev 2021
2
100

Case Report: Treatment of systemic mastocytosis with sunitinib.
Gerhard J Molderings, Lawrence B Afrin, Hans-Jörg Hertfelder, Stefan Brettner. F1000Res 2017
3
100

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
Miguel Piris-Villaespesa, Ivan Alvarez-Twose. Front Pharmacol 2020
5
100

Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients.
Philippe Casassus, Nadine Caillat-Vigneron, Antoine Martin, Jeanne Simon, Valérie Gallais, Patrice Beaudry, Virginie Eclache, Liliane Laroche, Pierre Lortholary, Martine Raphaël,[...]. Br J Haematol 2002
117
100



Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Jason Gotlib, Hanneke C Kluin-Nelemans, Cem Akin, Karin Hartmann, Peter Valent, Andreas Reiter. Expert Opin Biol Ther 2021
3
100

Successful treatment of mast cell activation syndrome with sunitinib.
Lawrence B Afrin, Frank M Cichocki, Kamal Patel, Gerhard J Molderings. Eur J Haematol 2015
12
100

How we diagnose and treat systemic mastocytosis in adults.
Robyn M Scherber, Uma Borate. Br J Haematol 2018
27
100

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Joseph D Growney, Jennifer J Clark, Jennifer Adelsperger, Richard Stone, Doriano Fabbro, James D Griffin, D Gary Gilliland. Blood 2005
198
100

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Javier I Muñoz-González, Iván Álvarez-Twose, María Jara-Acevedo, Roberta Zanotti, Cecelia Perkins, Mohamad Jawhar, Wolfgang R Sperr, Khalid Shoumariyeh, Juliana Schwaab, Georg Greiner,[...]. Lancet Haematol 2021
7
100

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Jason Gotlib, Hanneke C Kluin-Nelemans, Tracy I George, Cem Akin, Karl Sotlar, Olivier Hermine, Farrukh T Awan, Elizabeth Hexner, Michael J Mauro, David W Sternberg,[...]. N Engl J Med 2016
219
100

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.
Stéphane Barete, Olivier Lortholary, Gandhi Damaj, Isabelle Hirsch, Marie Olivia Chandesris, Caroline Elie, Mohamed Hamidou, Isabelle Durieu, Felipe Suarez, Bernard Grosbois,[...]. Blood 2015
71
100

KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
Andres C Garcia-Montero, Maria Jara-Acevedo, Cristina Teodosio, Maria Luz Sanchez, Rosa Nunez, Aranzazu Prados, Isabel Aldanondo, Laura Sanchez, Mercedes Dominguez, Luis M Botana,[...]. Blood 2006
319
100

Treatment of systemic mast-cell disease with cladribine.
A Tefferi, C Y Li, J H Butterfield, H C Hoagland. N Engl J Med 2001
115
100

Novel Approaches for Systemic Mastocytosis.
Luke Fletcher, Uma Borate. Curr Opin Hematol 2019
3
100

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Helga J Droogendijk, Hanneke J C Kluin-Nelemans, Jaap J van Doormaal, Arnold P Oranje, Arjan A van de Loosdrecht, Paul L A van Daele. Cancer 2006
91
100


A precision therapy against cancers driven by KIT/PDGFRA mutations.
Erica K Evans, Alexandra K Gardino, Joseph L Kim, Brian L Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson,[...]. Sci Transl Med 2017
79
100


KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.
M Arock, K Sotlar, C Akin, S Broesby-Olsen, G Hoermann, L Escribano, T K Kristensen, H C Kluin-Nelemans, O Hermine, P Dubreuil,[...]. Leukemia 2015
137
100

Imatinib for systemic mast-cell disease.
A Pardanani, M Elliott, T Reeder, C Y Li, E J Baxter, N C P Cross, A Tefferi. Lancet 2003
186
100

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
Andreas Hochhaus, Michele Baccarani, Francis J Giles, Philipp D le Coutre, Martin C Müller, Andreas Reiter, Helene Santanastasio, Mimi Leung, Steven Novick, Hagop M Kantarjian. J Cancer Res Clin Oncol 2015
37
100

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Hanneke C Kluin-Nelemans, Mohamad Jawhar, Andreas Reiter, Bjorn van Anrooij, Jason Gotlib, Karin Hartmann, Anja Illerhaus, Hanneke N G Oude Elberink, Aleksandra Gorska, Marek Niedoszytko,[...]. Theranostics 2021
6
100

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Ken-Hong Lim, Ayalew Tefferi, Terra L Lasho, Christy Finke, Mrinal Patnaik, Joseph H Butterfield, Rebecca F McClure, Chin-Yang Li, Animesh Pardanani. Blood 2009
331
100

The new tool "KIT" in advanced systemic mastocytosis.
William Shomali, Jason Gotlib. Hematology Am Soc Hematol Educ Program 2018
12
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.